URINE IMMUNOREACTIVE THROMBOXANE-B-2 IN RAT CARDIAC ALLOGRAFT-REJECTION

  • 1 January 1985
    • journal article
    • research article
    • Vol. 39  (1) , 6-8
Abstract
Increases in urinary excretion of immunoreactive thromboxane B2 (i-TXB2), the stable break-down product of thromboxane A2, have been described in kidney allograft rejection in patients. These findings were investigated by monitoring daily urine i-TXB2 excretion in a heterotopic cardiac allograft rat model using Lewis rats as recipients. To obtain differences in allograft survival, a donor was used that was either ACI or Lewis .times. Brown Norway F1 (L .times. B-NF1). The ACI-to-Lewis model rejected on day 6.2 .+-. 0.2 (n = 6). The L .times. B-NF1-to-Lewis model received, in addition, azathioprine (5 mg/kg per day) and rejected on day 9.1 .+-. 0.8 (n = 9). Urinary i-TXB2 excretion increased significantly in both groups, compared with i-TXB2 values measured following sham surgery or isograft transplantation. Thus, increases in urinary i-TXB2 appear to be associated with cardiac allograft rejection.